O2 has successfully trialled new technology to provide clearer phone calls for customers with hearing loss The trial was carried out with Mavenir and created a personalised hearing profile for each participant, allowing the network to automatically optimise calls in real time Working seamlessly in the background, the technology helped
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 10, 2026, 11:00 pm CET / 5:00 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 10, 2026, 11:00 pm CET / 5:00 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 10, 2026, 11:00 pm CET / 5:00 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)
$110 Million in Aggregate Financings to Accelerate Genio’s U.S. Commercial Launch Mont-Saint-Guibert, Belgium – June 10, 2026, 10:30 pm CET / 04:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), has completed
REGULATED INFORMATION Nyxoah Announces Closing of Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 10, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the
